Abstract

BackgroundMeasuring QoL is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL assessments throughout a patient’s cancer treatment especially in non-clinical trial patients. The aim of this study is to explore patient characteristics that may be associated with poor quality of life (QoL) in women with gynecologic cancers at two University of Arizona Cancer Center (UACC) sites.MethodsA cross-sectional survey was conducted among English speaking women with gynecologic malignancies at the University of Arizona Cancer Centers in Phoenix and Tucson from April 2012 to July 2015. The survey was a paper packet of questions that was distributed to cancer patients at the time of their clinic visit. The packet contained questions on demographic information, treatment, lifestyle characteristics, pelvic pain and Health-related quality of life (HRQoL). Measures included the generic and cancer-specific scores on the Functional Assessment of Cancer Therapy–General (FACT-G) and the Female Genitourinary Pain Index (GUPI). The total scores and subdomains were compared with descriptive variables (age, body mass index (BMI), diet, exercise, disease status, treatment and support group attendance) using Cronbach alpha (α), Spearman rank correlations (ρ), and Holm’s Bonferroni method.ResultsOne–hundred and forty-nine women completed the survey; 55% (N = 81) were older than 60 years, 38% (N = 45) were obese (BMI > 30), 46% (N = 66) exercised daily, and 84% (N = 111) ate one or more daily serving of fruit and vegetables. Women in remission, those who exercised daily and ate fruits/vegetables were less likely to have their symptoms impact their QoL. Younger women were more likely to report genitourinary issues (p = − 0.22) and overall problems with QoL (p = − 0.29) than older women. Among FACT-G support group responses, we found those that did not attend support groups had a significantly higher emotional wellbeing (p = 0.05).ConclusionsThis study identified potential areas of clinical focus, which aid in understanding our approach to caring for gynecologic cancer patients and improvement of their HRQoL. We identified that age, pelvic pain, and lifestyle characteristics have indicators to poor QoL in women with gynecologic cancers. In this population, younger women and those with pelvic pain complaints, poor diet and exercise habits should be targeted early for supportive care interventions to improve QoL throughout both treatment and survivorship.

Highlights

  • Measuring quality of life (QoL) is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL assessments throughout a patient’s cancer treatment especially in nonclinical trial patients

  • The impact of illness and treatment on quality of life (QoL) has received increasing recognition in recent years with the both the National Cancer Institute and the Food and Drug Administration who have mandated that the goals of cancer research should be to improve both survival and QoL [1]

  • QoL is defined as the level of satisfaction a person has with their physical (PWB), emotional (EWB), and social wellbeing (SWB) [6]

Read more

Summary

Introduction

Measuring QoL is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL assessments throughout a patient’s cancer treatment especially in nonclinical trial patients. Measuring QoL is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL. Since QoL is a multidimensional concept it Barnes et al Gynecologic Oncology Research and Practice (2018) 5:4 is important to assess how it affects various communities and populations so that interventions can be designed to help improve overall wellbeing in patients. Numerous instruments have been created and aim to measure patients’ QoL [13] One of these measures is the Health Related Quality of Life (HRQoL), which allows patients to self-report symptoms using patient-reported outcome (PRO) measures [4, 14]. The use of PRO, especially in oncology, has been shown to help with detection of problematic symptoms, symptom monitoring, satisfaction with patient care, and communication between clinicians and patients [15,16,17]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call